Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion type Assertion NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_head.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion description "[epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_provenance.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion evidence source_evidence_literature NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_provenance.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion SIO_000772 16651374 NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_provenance.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion wasDerivedFrom befree-20150227 NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_provenance.
- NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_assertion wasGeneratedBy ECO_0000203 NP368423.RAGNdf_TxbRM9N2x0_dMkTv8nI-7gr34a5LJNd6hCBBPQ130_provenance.